

Supplementary Table : Comparison of baseline characteristics and laboratory data among all patients

Variables	All n (1,520)	Ischemic stroke n (198)	Hemorrhage stroke n (34)	Non-stroke group n (1,277)	Ischemic + Hemorrhage stroke n (11)	p value
Age (years)	67.5 (13.1)	72.4 (10.7)	62.7 (13.4)	66.9 (13.2)	63.2 (10.2)	<0.001
Female gender (%)	492 (32.4)	43 (21.7)	16 (47.1)	428 (33.5)	5 (45.5)	<0.001
Diabetes Mellitus (%)	777 (51.1)	115 (58.0)	18 (52.9)	638 (50.0)	6 (54.5)	0.198
BMI (kg/m ²)	23.5 (4.4)	22.7 (3.6)	24.0 (5.2)	23.6 (4.5)	23.7 (4.1)	0.049
SBP (mmHg)	151 (26)	150 (27)	152 (22)	151 (26)	137 (25)	0.355
DBP (mmHg)	77 (15)	74 (16)	80 (15)	78 (15)	70 (18)	0.002
History of CAD (%)	255 (16.8)	34 (17.2)	7 (20.6)	212 (16.6)	2 (18.2)	0.861
Heart failure symptom (%)	467 (30.8)	74 (37.4)	9 (26.5)	379 (29.7)	5 (45.5)	0.08
CTR (%)	55.2 (7.2)	56.4 (7.2)	55.5 (6.7)	55.0 (7.2)	56.3 (4.3)	0.056
eGFR (ml/min/1.73m ²)	5.5 (2.2)	6.0 (2.6)	4.9 (1.4)	5.4 (2.2)	5.3 (1.3)	0.004
Serum creatinine (mg/dL)	8.97 (3.21)	8.33 (2.85)	9.50 (3.48)	9.05 (3.25)	8.43 (2.21)	0.019
BUN (mg/dL)	91.8 (30.5)	92.8 (28.6)	95.8 (29.7)	91.5 (30.8)	87.4 (23.8)	0.773
Hemoglobin (g/dL)	9.4 (1.6)	9.3 (1.5)	9.3 (1.6)	9.4 (1.6)	8.9 (1.8)	0.708
Serum albumin (g/dL)	3.20 (0.60)	3.17 (0.58)	3.29 (0.52)	3.20 (0.60)	3.49 (0.63)	0.285
Serum sodium (mEq/L)	138 (4)	138 (5)	137 (5)	138 (4)	139 (4)	0.609
Serum potassium (mEq/L)	4.6 (0.8)	4.5 (1.0)	4.7 (1.0)	4.6 (0.8)	5.0 (1.0)	0.169
Serum uric acid (mg/dL)	8.8 (2.4)	8.8 (2.2)	9.1 (2.7)	8.8 (2.5)	8.5 (1.0)	0.824
Serum adjusted calcium (mg/dL)	8.6 (1.1)	8.8 (1.0)	8.4 (1.0)	8.6 (1.1)	8.9 (0.9)	0.175
Serum phosphorus (mg/dL)	6.4 (1.9)	5.9 (1.8)	7.0 (1.8)	6.4 (1.9)	5.4 (0.8)	<0.001
Serum LDL-C (mg/dL)	90 (34)	89 (36)	93 (42)	90 (34)	77 (30)	0.681

Serum HDL-C (mg/dL)	45 (17)	44 (15)	48 (12)	45 (17)	37 (8)	0.455
Serum triglyceride (mg/dL)	125 (71)	118 (60)	134 (57)	126 (73)	116 (3)	0.444
Serum CRP (mg/dL) *	0.30 [0.10-1.35]	0.6 [0.18-2.14]	0.19 [0.90-1.50]	0.28 [0.10-1.28]	2.15 [0.28-5.98]	0.215
Intact PTH (pg/ml) *	291 [185-431]	261 [148-389]	405 [207-590]	295 [190-433]	205 [172-467]	<0.001
HCO ₃ ⁻ (mmol/L)	19.6 (4.9)	20.1 (5.2)	18.5 (5.0)	19.6 (4.9)	16.7 (6.5)	0.096
Use of CCBs (%)	1,199 (78.9)	158 (79.8)	27 (79.4)	1,005 (78.7)	9 (81.8)	0.989
Use of ACEIs/ARBs (%)	917 (60.3)	115 (58.1)	24 (70.6)	769 (60.2)	9 (81.8)	0.278
Use of β -blockers (%)	528 (34.7)	72 (36.4)	14 (41.2)	440 (34.5)	2 (18.2)	0.552
Use of Anti-platelet agents (%)	459 (30.2)	139 (70.2)	6 (17.6)	308 (24.1)	6 (54.5)	<0.001
Use of Warfarin (%)	106 (7.0)	20 (10.1)	2 (5.9)	82 (6.4)	2 (18.2)	0.095
Use of Loop diuretics (%)	1,000 (65.8)	132 (66.7)	20 (58.8)	843 (66.0)	5 (45.5)	0.404
Use of Statins (%)	608 (40.0)	87 (43.9)	15 (44.1)	497 (38.9)	9 (81.8)	0.018
Use of ESAs (%)	1,304 (85.8)	177 (89.4)	27 (79.4)	1,090 (85.4)	10 (90.9)	0.231

Mean, SD, Value (%), *Median, [interquartile range]

Mean, standard deviation,

BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, CAD; coronary artery disease, CTR; cardiothoracic ratio, eGFR; estimated glomerular filtration rate, BUN; blood urea nitrogen, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, CRP; C-reactive protein, PTH; parathyroid hormone, CCB; calcium channel blocker, ACEI; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blocker, ESA; erythropoiesis stimulating agent,